KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Retained Earnings (2020 - 2025)

Historic Retained Earnings for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to -$20.5 million.

  • AbCellera Biologics' Retained Earnings fell 11358.81% to -$20.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.5 million, marking a year-over-year decrease of 11358.81%. This contributed to the annual value of $116.9 million for FY2024, which is 5820.75% down from last year.
  • Latest data reveals that AbCellera Biologics reported Retained Earnings of -$20.5 million as of Q3 2025, which was down 11358.81% from $36.6 million recorded in Q2 2025.
  • AbCellera Biologics' Retained Earnings' 5-year high stood at $456.1 million during Q3 2022, with a 5-year trough of -$20.5 million in Q3 2025.
  • Moreover, its 5-year median value for Retained Earnings was $239.2 million (2024), whereas its average is $254.2 million.
  • As far as peak fluctuations go, AbCellera Biologics' Retained Earnings skyrocketed by 13437.94% in 2021, and later plummeted by 11358.81% in 2025.
  • Quarter analysis of 5 years shows AbCellera Biologics' Retained Earnings stood at $267.7 million in 2021, then skyrocketed by 59.22% to $426.2 million in 2022, then crashed by 34.35% to $279.8 million in 2023, then plummeted by 58.21% to $116.9 million in 2024, then tumbled by 117.56% to -$20.5 million in 2025.
  • Its last three reported values are -$20.5 million in Q3 2025, $36.6 million for Q2 2025, and $71.3 million during Q1 2025.